COA Submits Comments on CMS' Proposed CAR T-Cell Coverage Decision

Article

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy, saying that while they are pleased with the direction of covering the therapy, they have concerns with the language included in the memo.

According to COA, CMS should not limit CAR T-cell coverage to hospitals, with many community oncology practices having the experience and capability to administer the therapy. Read the full comment letter.

Recent Videos
Cure SMA Treatment Recommendations
James Beck, PhD, the chief scientific officer of the Parkinson’s Foundation
James Beck, PhD, the chief scientific officer of the Parkinson’s Foundation
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Related Content
World Lupus Day 2025: Cell Therapy Continues its March of Progress

World Lupus Day 2025: Cell Therapy Continues its March of Progress

Noah Stansfield
May 10th 2025
Article

In observance of World Lupus Day, held annually on May 10, we took a look back at recent progress in bringing cell therapy to this autoimmune disease.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Linda Marbán, PhD, the CEO of Capricor Therapeutics

FDA States Advisory Committee Meeting Will be Held for Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel

Noah Stansfield
May 9th 2025
Article

In a mid-cycle review meeting, the agency also noted that the review committee found no major deficiencies with the BLA package.

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

Around the Helix: Cell and Gene Therapy Company Updates – May 7, 2025

Around the Helix: Cell and Gene Therapy Company Updates – May 7, 2025

Noah Stansfield
May 7th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

J&J's XLRP Gene Therapy Bota-Vec Falls Short of Primary End Points

J&J's XLRP Gene Therapy Bota-Vec Falls Short of Primary End Points

Kassi Filkins
May 7th 2025
Article

J&J purchased the full rights to bota-vec in a 2023 deal with MeiraGTx

© 2025 MJH Life Sciences

All rights reserved.